You are correct with pointing towards a more respected IB Group with the larger firms or respected Biotech Investment Groups like Baker Bros, etc, but I did note that apparently the founders at LPC were both Harvard Grads and lawyers....also, I did see that 2 of the people there are qualified and specializing in Biotech....
This was a good post as you addressed something that is correct!
Which investment bank would have their clients buy into a company run by a misleader/liar/procrastinator? No bank wants to touch a company that takes 6-12 months after study completion to PR data!
So what? Missling has managed the company's finances just fine without those institutional investors.
Once there is an approved drug those instys will be knocking on the door. My take is that Anavex is still viewed by those instys as a high risk, untried approach to treating CNS diseases. As such they don't want the risk. Once the risk is reduced to a level they find acceptable they will buy into Anavex.
The MOA still has to be validated by an approval. Once that happens a whole lot of folks will take Anavex seriously. Till then it is just another high risk developmental biotech with an extremely novel approach addressing diseases that have proven to be intractable so far.
I think you are putting the cart before the horse.
News 
Market Data 
Discover 
